You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

May 22, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

SGLT2 inhibitors for diabetes may cause ketoacidosis, FDA warns

FDA is warning that the type 2 diabetes drugs canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization. » Read more

Hep C patient sues Blue Cross for denying Harvoni coverage

A hepatitis C patient is suing Blue Cross because the payer will not cover her Harvoni medication. » Lawsuit details

Continuing Education

MTM essentials for asthma management: Part 2

This month's CE activity is part of the CE series, MTM for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review the stepwise approach to the management of pediatric and adult asthma and the pharmacotherapies commonly used in asthma treatment.

To read and print the article with TEST questions, click here

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT30-PYJ23.


Announcement: The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration has been uploaded for your convenience. Current users do not need to register. To review you registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

The best aspirin dose to help heart disease patients is yet to be determined

The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors this week approved a 3-year, $14 million clinical trial designed to determine the best dose of aspirin to use to prevent heart attacks and strokes in people with heart disease. » Details

 

RELATED ARTICLES

FDA: Keep boxed warning on Chantix

FDA warns about serious reactions to Harvoni, Sovaldi

RESOURCES

Latest Clinical News

Powered by Modern Medicine UBM  logo

UBM MEDICA